The filing is a routine corporate update with no new financial data. Monitor for F351 NMPA decision in early 2027 and IND filings for CG923308 and CG620953 in Q1 2027, which are the next key catalysts.
Price Chart
Executive Summary
Gyre Therapeutics filed an 8-K furnishing an updated corporate investor presentation. The presentation highlights the company's integrated US-China R&D platform, its commercial ETUARY pirfenidone franchise in China (FY26 revenue guidance of $100.5M-$111M), and a diversified pipeline of targeted protein degraders and degrader antibody conjugates. Key catalysts include a potential F351 launch in early 2027 following NDA acceptance in China, and planned IND submissions for CG923308 and CG620953 in Q1 2027. The filing is a routine business update with no new material financial disclosures.
Key Facts
- ETUARY FY26 total revenue guidance of $100.5M-$111M.
- F351 (Hydronidone) NDA accepted by China NMPA in May 2026; potential launch in early 2027.
- CG923308 (CDK2/Cyclin E degrader) and CG620953 (TYK2/JAK1 degrader) IND submissions planned for Q1 2027.
- CG001419 (TRK degrader) Phase 1 data showed DC50 of 2.1 ng/mL and DC90 of 16 ng/mL; planning Phase 2 initiation.
- CG009301 (GSPT1 degrader) Phase 1 dose escalation ongoing in China for high-risk hematologic malignancies.
- Company has 370 commercial personnel across 3,000+ hospitals and pharmacies in China.
Financial Impact
ETUARY FY26 revenue guidance of $100.5M-$111M; no new financial results reported.
Risk Factors
- Clinical development risk for pipeline assets (CG923308, CG620953, CG009301, CG001419).
- Regulatory and commercial risk for F351 launch in China.
- Reliance on China operations for revenue and R&D cost efficiency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035189 |
| Document: ef20081441_8k.htm | 0001140361-26-035189 |
| Document: 0001140361-26-035189-index-headers.html | 0001140361-26-035189 |
| Document: 0001140361-26-035189-index.html | 0001140361-26-035189 |
| Document: 0001140361-26-035189.txt | 0001140361-26-035189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.85 | awaiting T+20 | — | $6.07 (+3.76%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.07 (−6.18%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.07 (−8.72%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.07 (+9.00%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.07 (−1.30%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.07 (−4.26%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.07 (+9.17%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.07 (−7.33%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.07 (−23.36%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.07 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers